Detail akcie TG Therap online

Business Summary: TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Financial Summary: BRIEF: For the six months ended 30 June 2025, TG Therapeutics Inc revenues increased 91% to $262M. Net income totaled $33.2M vs. loss of $3.8M. Revenues reflect License, milestone and other revenue increase from $13.9M to $122M, Product increase of 14% to $140M. Net Income reflects Selling/General/Admin Expense decrease of 32% to $23.7M (expense), Other income increase from $2.6M to $6.4M (income).